Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ninian N Lang

Showing results (61-70 of 88) with videos related to

Pageof 9
Sort By:
JAMA Cardiology|October 3, 2022
Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVERAkshay S Desai, Pardeep S Jhund, Brian L Claggett, et al.
Heart (British Cardiac Society)|August 10, 2022
Rationale and design of a randomised trial of intravenous iron in patients with heart failurePaul R Kalra, John Gf Cleland, Mark C Petrie, et al.
JAMA Cardiology|June 23, 2021
Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection FractionChristopher J Rush, Colin Berry, Keith G Oldroyd, et al.
JACC. Cardiooncology|October 9, 2025
Prospective Evaluation of the Cardiovascular Effects of BRAF and MEK Inhibitors in Patients With MelanomaClaire Glen, Stephen J H Dobbin, Kenneth Mangion, et al.
Circulation. Heart Failure|June 29, 2022
Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline CardiotoxicityPeter A Henriksen, Peter Hall, Olga Oikonomidou, et al.
Journal of the American Heart Association|February 1, 2021
Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HFSolmaz Ehteshami-Afshar, Leanne Mooney, Pooja Dewan, et al.
ESC Heart Failure|May 8, 2024
Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and designJaclyn Carberry, Mark C Petrie, Matthew M Y Lee, et al.
Heart (British Cardiac Society)|February 12, 2025
Age-stratified effects of intravenous ferric derisomaltose in heart failure with iron deficiency: insights from the IRONMAN trialShirley Sze, Iain Squire, Paul R Kalra, et al.
Circulation|October 5, 2023
Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled TrialNovalia P Sidik, Bethany Stanley, Robert Sykes, et al.
European Journal of Heart Failure|October 25, 2024
Effect of correcting iron deficiency on the risk of serious infection in heart failure: Insights from the IRONMAN trialPaul W Foley, Paul R Kalra, John G F Cleland, et al.
Pageof 9

Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
JAMA Cardiology|October 3, 2022
Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVERAkshay S Desai, Pardeep S Jhund, Brian L Claggett, et al.
Heart (British Cardiac Society)|August 10, 2022
Rationale and design of a randomised trial of intravenous iron in patients with heart failurePaul R Kalra, John Gf Cleland, Mark C Petrie, et al.
JAMA Cardiology|June 23, 2021
Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection FractionChristopher J Rush, Colin Berry, Keith G Oldroyd, et al.
JACC. Cardiooncology|October 9, 2025
Prospective Evaluation of the Cardiovascular Effects of BRAF and MEK Inhibitors in Patients With MelanomaClaire Glen, Stephen J H Dobbin, Kenneth Mangion, et al.
Circulation. Heart Failure|June 29, 2022
Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline CardiotoxicityPeter A Henriksen, Peter Hall, Olga Oikonomidou, et al.
Journal of the American Heart Association|February 1, 2021
Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HFSolmaz Ehteshami-Afshar, Leanne Mooney, Pooja Dewan, et al.
ESC Heart Failure|May 8, 2024
Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and designJaclyn Carberry, Mark C Petrie, Matthew M Y Lee, et al.
Heart (British Cardiac Society)|February 12, 2025
Age-stratified effects of intravenous ferric derisomaltose in heart failure with iron deficiency: insights from the IRONMAN trialShirley Sze, Iain Squire, Paul R Kalra, et al.
Circulation|October 5, 2023
Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled TrialNovalia P Sidik, Bethany Stanley, Robert Sykes, et al.
European Journal of Heart Failure|October 25, 2024
Effect of correcting iron deficiency on the risk of serious infection in heart failure: Insights from the IRONMAN trialPaul W Foley, Paul R Kalra, John G F Cleland, et al.
Pageof 9